2023 annual financial data
SAB Biotherapeutics 2023 Net margin
Direct answer
Net margin was -1,884.5%.
Operating income was -38,075,000 USD and net income was -42,194,000 USD.
Operating cash flow was -25,119,405 USD.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,239,000 USD
- Operating income
- -38,075,000 USD
- Net income
- -42,194,000 USD
- Operating cash flow
- -25,119,405 USD